Back to Search
Start Over
Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters
- Source :
- Cell Cycle, article-version (VoR) Version of Record, Holst, C B, Pedersen, H, Obara, E A A, Vitting-Seerup, K, Jensen, K E, Skjøth-Rasmussen, J, Lund, E L, Poulsen, H S, Johansen, J S & Hamerlik, P 2021, ' Perspective : targeting VEGF-A and YKL-40 in glioblastoma–matter matters ', Cell Cycle, vol. 20, no. 7, pp. 702-715 . https://doi.org/10.1080/15384101.2021.1901037
- Publication Year :
- 2021
- Publisher :
- Taylor & Francis, 2021.
-
Abstract
- Glioblastomas (GBM) are heterogeneous highly vascular brain tumors exploiting the unique microenvironment in the brain to resist treatment and anti-tumor responses. Anti-angiogenic agents, immunotherapy, and targeted therapy have been studied extensively in GBM patients over a number of decades with minimal success. Despite maximal efforts, prognosis remains dismal with an overall survival of approximately 15 months. Bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) antibody, underwent accelerated approval by the U.S. Food and Drug Administration in 2009 for the treatment of recurrent GBM based on promising preclinical and early clinical studies. Unfortunately, subsequent clinical trials did not find overall survival benefit. Pursuing pleiotropic targets and leaning toward multitarget strategies may be a key to more effective therapeutic intervention in GBM, but preclinical evaluation requires careful consideration of model choices. In this study, we discuss bevacizumab resistance, dual targeting of pro-angiogenic modulators VEGF and YKL-40 in the context of brain tumor microenvironment, and how model choice impacts study conclusions and its translational significance.
- Subjects :
- 0301 basic medicine
Vascular Endothelial Growth Factor A
YKL-40
Angiogenesis
VEGF receptors
03 medical and health sciences
Mice
0302 clinical medicine
Antineoplastic Agents, Immunological
Drug Delivery Systems
Mice, Inbred NOD
medicine
Tumor Microenvironment
Animals
Humans
mouse models
Chitinase-3-Like Protein 1
Molecular Biology
biology
Brain Neoplasms
Perspective (graphical)
glioblastoma
Cell Biology
medicine.disease
VEGF
Xenograft Model Antitumor Assays
nervous system diseases
Bevacizumab
030104 developmental biology
Drug Resistance, Neoplasm
030220 oncology & carcinogenesis
biology.protein
Cancer research
Developmental Biology
Glioblastoma
Research Article
Research Paper
Subjects
Details
- Language :
- English
- ISSN :
- 15514005 and 15384101
- Volume :
- 20
- Issue :
- 7
- Database :
- OpenAIRE
- Journal :
- Cell Cycle
- Accession number :
- edsair.doi.dedup.....455c7e1e0ae71ee8c04676ce6038a836